LAB vs T · rev $174.4M vs P/E 7.4, rev $125.65B
Standard Biotools Inc (LAB) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
LAB currently screens at market cap $317.1M. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the LAB and T stock pages for the full models.
Not investment advice.